For a CKD patient with resistant hypertension despite ACE inhibitor therapy, what is a key consideration in selecting additional antihypertensives?

• A. Monitor potassium and kidney function; RAAS blockade can cause hyperkalemia; choose agents that do not worsen potassium excessively, and adjust
• B. Add a thiazide diuretic regardless of potassium
• C. Avoid any additional antihypertensives
• D. Aggressively escalate ACE inhibitors without monitoring labs

Answer: (A)

When caring for a CKD patient with hypertension that remains high despite an ACE inhibitor, the big issue is balancing blood pressure control with the safety of potassium and kidney function. ACE inhibitors and other RAAS blockers can raise potassium levels because they reduce aldosterone, and CKD already impairs the kidneys’ ability to excrete potassium. So, any additional antihypertensive should be chosen with close attention to potassium and creatinine (or eGFR).

The best approach is to monitor potassium and kidney function as you add or adjust therapy, and to select agents that are less likely to push potassium higher. If potassium creeps up, you can adjust the ACE inhibitor dose, add a diuretic that helps remove excess potassium, or choose another class of antihypertensive (such as a calcium channel blocker or a loop diuretic) while continuing to monitor labs and blood pressure. This keeps BP reducing while safeguarding electrolytes and renal function.

Adding a diuretic regardless of potassium status isn’t appropriate in CKD, since efficacy depends on GFR and electrolyte effects must be considered. Not adding any additional antihypertensives leaves resistant hypertension untreated. Escalating ACE inhibitors without monitoring labs risks severe hyperkalemia and worsening kidney function.